A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML).
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms OPTIM IMATINIB
- 08 Dec 2015 Status changed from recruiting to completed, according to the results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 28 Mar 2012 Planned end date (14 Jun 2013) added as reported by European Clinical Trials Database.